| pubmed-article:18594541 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C1559154 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C1333355 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0681890 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18594541 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18594541 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18594541 | pubmed:dateCreated | 2008-7-2 | lld:pubmed |
| pubmed-article:18594541 | pubmed:abstractText | The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy. The purpose of this study was to evaluate the role of ERCC1 expression as a predictive marker of survival in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). ERCC1 expression was assessed by immunohistochemical staining. The median age of the 45 patients analysed was 56 years (range 27-75 years), and 82% were men; 73% of all specimens showed high expression of ERCC1. The overall tumour response rate after CCRT was 89%. The median follow-up was 53.6 months (95% CI, 34.5-72.7 months). The 3-year progression-free survival (PFS) and overall survival (OS) rates were 58.7 and 61.3%, respectively. Univariate analyses showed that patients with low expression of ERCC1 had a significantly higher 3-year PFS (83.3 vs 49.4%, P=0.036) and OS (91.7 vs 45.5%, P=0.013) rates. Multivariate analysis showed that low expression of ERCC1 was an independent predictor for prolonged survival (HR, 0.120; 95% CI, 0.016-0.934, P=0.043). These results suggest that ERCC1 expression might be a useful predictive marker of locally advanced SCCHN in patients treated with cisplatin-based CCRT. | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18594541 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18594541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18594541 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18594541 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18594541 | pubmed:issn | 1532-1827 | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:HanJJ | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:LeeS KSK | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:KimH SHS | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:ParkKK | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:YiS YSY | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:ChoO KOK | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:BaurJ RJR | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:JunH JHJ | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:AhnY CYC | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:JinQ WQW | lld:pubmed |
| pubmed-article:18594541 | pubmed:author | pubmed-author:JeongH-SHS | lld:pubmed |
| pubmed-article:18594541 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18594541 | pubmed:day | 8 | lld:pubmed |
| pubmed-article:18594541 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:18594541 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18594541 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18594541 | pubmed:pagination | 167-72 | lld:pubmed |
| pubmed-article:18594541 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:meshHeading | pubmed-meshheading:18594541... | lld:pubmed |
| pubmed-article:18594541 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18594541 | pubmed:articleTitle | ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. | lld:pubmed |
| pubmed-article:18594541 | pubmed:affiliation | Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea. | lld:pubmed |
| pubmed-article:18594541 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:2067 | entrezgene:pubmed | pubmed-article:18594541 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18594541 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18594541 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18594541 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18594541 | lld:pubmed |
